RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff Reposted - from June 24, 2022
The pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, particularly now that soon-to-come generic competition is on the horizon with Big Pharma's looming patent cliff, according to [the Global consulting company] PwC.
To mitigate this emerging threat Big Pharma will seek to ramp-up innovation and it's M&A activities. Of interest for Big Pharma hunting for biotechs are early-stage companies and "bolt-on" transactions, that are in the range of US$5 Billion to US$15 Billion.
As an early-mid stage biotech company with the complementary drug pelareorep to immune checkpoint inhibitors, ONCY is well-positioned as a "bolt-on" acquisition for Big Pharma, [who currently have IO agents such as] immune checkpoint inhibitors, PARP inhibitors, CAR-T and bi-specific therapies, like those discussed on this message board.
Furthermore, ONCY's biomarkers will enable oncologists/doctors to identify which patients would most benefit from the IO combination of pelareorep + immune checkpoint inhibitors, as well as further giving these doctors the ability to monitor the benefit of the IO combination throughout the course of therapy.
…
June 2022 - A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030.
- per 'pharmalive - looming-patent-cliff-will-be-pharmas-moment-of-truth'
Take-aways:
Companies won’t make up the losses with their current pipelines or by adding an asset or two this time.
“The replenishment rate – the ability to make up the losses within five years – is decreasing."
Many of the affected drugs are biologics, including – in the latter half of the decade – newer drugs like Keytruda.
“With about $180 billion in ‘dry powder’ sitting with the top 12 companies alone, we can anticipate more mergers and acquisitions activity,”
“So, if you are a very diverse pharma company, your best move is to focus,” according to Maria Whitman, global head of ZS Associates’ pharmaceutical and biotech practice. Conversely, if your company is focused on one key area, consider what that market will be in the future, where you should go next and how you can have impact. “Oncology, for example, represents 22% of worldwide revenues now and will represent 27% in 2030, but it is also the number one area of development, and the bar of “unmet need” will be higher for differentiation.
The Era of Precision Medicine is upon us.
“The next era is about outcomes,” Whitman contends, “and pharma is at a moment of truth in company strategies around focus, innovation and in particular, how they can affect patient outcomes beyond the medicine. For example, in the past, we spent time helping the doctor find the patient, and now we have to help the patient find the right doctor and the right care.”
[ ONCY has positioned pelareorep for this new era.
ONCY's pelareorep + immune checkpoint inhibitors (ICI), complimented by the predictive diagnostic biomarkers being developed for pelareorep, is demonstrating that this IO treatment combination delivered through optimal route of systemic delivery (IV)], is able to be given to the right patient, at the right time, in the right disease, resulting in synergistic treatment effectiveness and durability of treatment.]